Please assess the completion status of the following clinical trial:

Trial Title: Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female \>18 or \<70 years of age~* Willing to practice effective contraception during the study and be willing and able to continue contraception for 1 month (females) or 3 months (males) after the last dose of study treatment~* Confirmed diagnosis of chronic sinusitis with nasal polyps~* Documented history of nasal eosinophilia~* Documented peripheral absolute eosinophil count \>300 cells/μL~* Bilateral total polyp score of \>4~* Sino-nasal outcome test (SNOT-22) score of \>7~* Using an intranasal corticosteroid spray or irrigation (\< 1000 μg/day beclomethasone or equivalent)~Exclusion Criteria:~* Acute sinusitis, concurrent nasal infection, or subjects who have had a nasal or upper respiratory tract infection within 2 weeks prior to baseline~* CT scan suggestive of allergic fungal rhinosinusitis~* Nasal septal deviation that would occlude at least one nostril~* Nasal surgery (including polypectomy) within 6 months prior to baseline~* History of more than 5 sinonasal surgeries requiring general anesthesia~* History of more than 2 sinonasal surgeries that changed the lateral wall of the nose~* History of cystic fibrosis, primary ciliary's dysfunction or Kartagener's syndrome~* History of diagnosis with a parasitic infection~* Hospitalization or emergency treatment for the treatment of asthma two or more times in the 12 months prior to baseline~* Hospitalization for an acute asthmatic attack within 4 weeks prior to baseline~* Forced expiratory volume (FEV1) of \<60% of predicted normal range~* Treatment with a systemic corticosteroid or intra-polyp corticosteroid within 8 weeks prior to baseline or anticipated need for systemic corticosteroids during the study treatment period~* Utilization of rescue oral corticosteroids for asthma or chronic sinusitis exacerbation more than one time within the past 1 year~* Treatment with an investigational drug in the previous 30 days or 5-half-lives, whichever is longer~* Treatment with a monoclonal antibody therapy including omalizumab (Xolair®), within 5-half-lives~* Treatment with zileuton (Zyflo®) within 4 weeks of baseline~* Treatment with pramipexole (Mirapex®) within 4 weeks of baseline~* History of malignancy, including solid tumors and hematologic malignancies (except basal cell and squamous cell cancers of the skin that have been completely excised and cured)~* History of human immunodeficiency virus (HIV) or hepatitis B or C~* History of unstable or severe cardiac, hepatic, or renal disease, or other medically significant illness~* Medical or other condition likely to interfere with subject's ability to undergo study procedures, adhere to visit schedule or comply with study requirements~* Absolute neutrophil count \<2000 cells/μL at screening, or any documented history of neutropenia~* Total IgE \>1500 IU/ml at any visit prior to baseline~* Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) of ≤80 mg/dL at screening (estimation of creatinine clearance using the MDRD formula)~* History of long QT syndrome or arrhythmia~* Prolongation of QT/QTc interval (e.g., repeated demonstration of a QT/QTc interval \>450 ms) at screening or pre-dose on day 1~* Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTc interval changes at screening or pre-dose on day 1, including any of the following:~  * PR interval \>210 ms;~ * QRS \>110 ms;~ * Heart rate \<45 bpm or \>100 bpm (average of 3 assessments).~* Pregnant women or women breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- dexpramipexole (Type: EXPERIMENTAL): dexpramipexole 150 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).